Top

International Journal of Colorectal Disease

Published in:

01-06-2010 | Original Article

The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma

Authors: Shao-Liang Han, Chang Xu, Xiu-Ling Wu, Jun-Lin Li, Zhi Liu, Qi-Qiang Zeng

Published in: International Journal of Colorectal Disease | Issue 6/2010

Abstract

Background

Various evidence show that CD97 plays an important role in tumor differentiation, migration, invasiveness, and metastasis by binding its cellular ligand CD55. CD55 is a complement regulatory protein expressed by cells to protect them from bystander attack by complement, and it has been shown to be an indicator of poor prognostic in several cancers.

Methods

CD97 and CD55 stains were detected in tumor tissues from 71 cases of rectal adenocarcinomas and their corresponding normal colorectal tissues by immunohistochemistry.

Results

The expressions of CD97 and CD55 in rectal tumor tissues were significantly higher than those in normal colorectal tissues (P < 0.05, both). The patients with recurrence and/or metastasis had significantly higher expressions of CD97 at tumor cells and CD55 at stroma (67.8% [21/31] and 63.6% [21/33]) at the invasion front than those patients without recurrence and/or metastasis (25.0% [10/40] and 26.3% [10/38]). The expression of CD97 at tumor cell at the invasion front showed modest correlation with that of CD55 in the stroma at the invasion front(r = 0.392, P < 0.01). Univariate analysis revealed that lymph node metastasis (P = 0.001), stages II–IV (P = 0.026), and strong CD97 expression at tumor invasion front (P = 0.002) were shown to have a significant adverse impact on the postoperative survival rate. Moreover, lymph node metastasis (P = 0.037) and strong CD97 expression (P = 0.015) were associated with poor survival in a multivariate analysis.

Conclusions

Elevated expression of CD97 and its ligand CD55 at the invasion front correlate with tumor recurrence and metastasis, and CD95 may be a poor prognostic factor for rectal adenocarcinoma.

Galle J, Sittig D, Hanisch I et al (2006) Individual cell-based models of tumor–environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol 169:1802–1811CrossRefPubMed

Guarino M (2007) Epithelial–mesenchymal transition and tumor invasion. Int J Biochem Cell Biol 39:2153–2160CrossRefPubMed

Guzińska-Ustymowicz K (2005) The role of tumor budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res 25:1269–1272PubMed

Kurokawa H, Zhang M, Matsumoto S et al (2005) The high prognostic value of the histologic grade at the deep invasive front of tongue squamous cell carcinoma. J Oral Pathol Med 34:329–333CrossRefPubMed

Prall F (2007) Tumour budding in colorectal carcinoma. Histopathology 50:151–162CrossRefPubMed

Staub E, Groene J, Heinze M et al (2007) Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer 6:79CrossRefPubMed

Brabletz T, Jung A, Reu S et al (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98:10356–10361CrossRefPubMed

Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194:701–704PubMed

Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C (2005) Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B 6:913–918CrossRefPubMed

10.

Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52:638–642CrossRefPubMed

11.

Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE (2004) Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 10:2797–2803CrossRefPubMed

12.

Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84:623–630CrossRefPubMed

13.

Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26:281–290CrossRefPubMed

14.

Sivridis E, Giatraomanolaki A, Koukourakis MI (2005) Proliferating fibroblasts at the invading tumor edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity and oxidative stress. J Clin Pathol 58:1033–1038CrossRefPubMed

15.

Steinert M, Wobus M, Boltze C et al (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161:1657–1667PubMed

16.

Liu Y, Chen L, Peng S et al (2005) The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep 14:1413–1420PubMed

17.

Wobus M, Huber O, Hamann J, Aust G (2006) CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Mol Carcinog 45:881–886CrossRefPubMed

18.

Wang T, Tian L, Haino M et al (2007) Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun 75:1144–1153CrossRefPubMed

19.

Aust G, Steinert M, Schütz A et al (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 118:699–707CrossRefPubMed

20.

Aust G, Eichler W, Laue S et al (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57:1798–1806PubMed

21.

Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG (2006) Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol Immunother 55:987–995CrossRefPubMed

22.

Mikesch JH, Buerger H, Simon R, Brandt B (2006) Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta 1766:42–52PubMed

23.

Shimo K, Mizuno M, Nasu J et al (2004) Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma. Gastroenterol Hepatol 19:643–647CrossRef

24.

Li L, Spendlove I, Morgan J, Durrant LG (2001) CD55 is over-expressed in the tumor environment. Br J Cancer 84:80–86CrossRefPubMed

25.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

26.

Wobus M, Vogel B, Schmücking E, Hamann J, Aust G (2004) N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer 112:815–822CrossRefPubMed

27.

Boltze C, Schneider-Stock R, Aust G et al (2002) CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol Int 52:83–88CrossRefPubMed

28.

Hoang-Vu C, Bull K, Schwarz I et al (1999) Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 84:1104–1109CrossRefPubMed

29.

Mustafa T, Eckert A, Klonisch T et al (2005) Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 14:108–119PubMed

30.

Maruyama K, Ochiai A, Akimoto S et al (2000) Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59:302–309CrossRefPubMed

31.

Huang D, Du X (2008) Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol 28; 14:1823–1827

32.

Mustafa T, Klonisch T, Hombach-Klonisch S et al (2004) Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 24:285–294PubMed

33.

Ikeda J, Morii E, Liu Y et al (2008) Prognostic significance of CD55 expression in breast cancer clin. Cancer Res 14:4780–4786CrossRef

34.

Zlobec I, Lugli A (2008) Prognostic and predictive factors in colorectal cancer. Postgrad Med J 84:403–411CrossRefPubMed

Title: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma
Authors: Shao-Liang Han
Chang Xu
Xiu-Ling Wu
Jun-Lin Li
Zhi Liu
Qi-Qiang Zeng
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 6/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-0926-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Impact of using elastic stains for detection of venous invasion in the prognosis of patients with lymph node negative colorectal cancer

Loss of cell-surface receptor EphB2 is important for the growth, migration, and invasiveness of a colon cancer cell line

Smoking and inflammatory bowel diseases: what in smoking alters the course?

Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis

Colovesical, coloenteric, colocutaneous fistula, and hip septic arthritis secondary to sigmoid diverticulitis

Efficacy and safety of colonic stenting for malignant disease in the elderly